Literature DB >> 2793231

Functional interactions of IL2 and TNF in the differentiation of LGL into LAK effectors.

J Y Blay1, J Bertoglio, D Fradelizi, S Chouaib.   

Abstract

We have previously reported on the synergistic effect of IL2 and TNF on the differentiation of LGL into LAK effectors. In the present study, we have further investigated the molecular basis of this synergistic mechanism and examined the role of TNF in the induction of LAK activity. We show that the generation of optimal LAK activity by low doses of IL-2 in the presence of TNF involves the induction of high-affinity IL2 receptors on LGL and occurs without promoting significant proliferation, suggesting a functional activation rather than a proliferative expansion of LAK precursors. Using blocking studies with anti-Tac and with an anti-IL2 (IHII), which specifically inhibits the binding of IL2 to the p75 IL2 receptor component, we also show that both the p55 and the p75 are involved in the increase in TNF binding sites on LGL and the subsequent acquisition of LAK activity. We also demonstrate that the failure of low doses of IL2 to induce LAK activity is related to their incapacity to induce TNF production. Moreover, when specific antibodies against TNF were added to the culture, the differentiation of LGL into LAK effectors by optimal concentrations of IL2 in our system (2.5-5.0 ng/ml) was partially inhibited. This suggests that TNF may be a physiologic mediator in the sequential activation stages of LGL into LAK effectors.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2793231     DOI: 10.1002/ijc.2910440407

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  11 in total

1.  Suppression of lymphokine-activated killer (LAK) cell induction mediated by interleukin-4 and transforming growth factor-beta 1: effect of addition of exogenous tumour necrosis factor-alpha and interferon-gamma, and measurement of their endogenous production.

Authors:  B Brooks; K Chapman; J Lawry; A Meager; R C Rees
Journal:  Clin Exp Immunol       Date:  1990-12       Impact factor: 4.330

2.  Involvement of cyclic adenosine monophosphate in the interleukin 4 inhibitory effect on interleukin 2-induced lymphokine-activated killer generation.

Authors:  J Y Blay; D Branellec; E Robinet; B Dugas; F Gay; S Chouaïb
Journal:  J Clin Invest       Date:  1990-06       Impact factor: 14.808

3.  TNFα Augments Cytokine-Induced NK Cell IFNγ Production through TNFR2.

Authors:  Wagdi Almishri; Tania Santodomingo-Garzon; Tyson Le; Danuta Stack; Christopher H Mody; Mark G Swain
Journal:  J Innate Immun       Date:  2016-08-25       Impact factor: 7.349

4.  Longer local retention of adoptively transferred T-LAK cells correlates with lesser adhesion molecule expression than NK-LAK cells.

Authors:  T Yamamoto; K Yoneda; T Osaki; N Yoshimura; N Akagi
Journal:  Clin Exp Immunol       Date:  1995-04       Impact factor: 4.330

5.  Effects of tumour necrosis factor-alpha (TNF-alpha), IL-1 beta and monocytes on lymphokine-activated killer (LAK) induction from natural killer (NK) cells and T lymphocytes.

Authors:  K Yoneda; T Osaki; T Yamamoto; E Ueta
Journal:  Clin Exp Immunol       Date:  1993-08       Impact factor: 4.330

6.  Antibodies to tumor necrosis factor: a component of B cell immune responses with a role in tumor/host interaction.

Authors:  J A Barbuto; W J Grimes; E M Hersh
Journal:  Cancer Immunol Immunother       Date:  1995-01       Impact factor: 6.968

7.  Immunomodulation during prolonged treatment with combined interleukin-2 and interferon-alpha in patients with advanced malignancy.

Authors:  A von Rohr; A K Ghosh; N Thatcher; P L Stern
Journal:  Br J Cancer       Date:  1993-01       Impact factor: 7.640

8.  Tumour-infiltrating lymphocytes bear the 75 kDa tumour necrosis factor receptor.

Authors:  L Trentin; R Zambello; P Bulian; A Cerutti; C Enthammer; M Cassatella; D Nitti; M Lise; C Agostini; G Semenzato
Journal:  Br J Cancer       Date:  1995-02       Impact factor: 7.640

9.  Temporal sequence and cellular origin of interleukin-2 stimulated cytokine gene expression.

Authors:  K A Saraya; F R Balkwill
Journal:  Br J Cancer       Date:  1993-03       Impact factor: 7.640

10.  Enhancement by monocytes of perforin production and its gene expression by human CD8+ T cells stimulated with interleukin-2.

Authors:  K Sugihara; S Sone; M Shono; A Nii; M Munekata; K Okumura; T Ogura
Journal:  Jpn J Cancer Res       Date:  1992-11
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.